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Purpose: Modeling excess and relative mortality represents two ways of considering general 
population mortality rates (ie, background mortality) in cohort studies. Excess mortality is 
obtained by subtracting the expected mortality from the observed mortality (additive hazard 
model). Relative mortality is obtained by dividing the observed mortality by the expected 
mortality (multiplicative hazard model). Our first objective was to compare the results of these 
two models in a population-based cohort including 5115 dialyzed patients older than 70 years 
(mean age 79 years, range 70–97 years). Our second objective was to explore an alternative 
model combining both excess and relative mortality.
Patients and methods: Effects of covariates on excess mortality and relative mortality were 
assessed using a generalized linear model and a Cox model, respectively. The model, combining 
both excess and relative mortality, is derived from the Aalen model.
Results: The effect of age and sex was different according to the additive or multiplicative 
model used, whereas the effect of the first modality of dialysis or the primary nephropathy was 
similar. Because there was no evidence of lack of fit, the choice of one of these two models was 
not obvious. The combined model showed that the two components, additive and multiplicative, 
had to be kept. In this case, the combined model led to results similar to the pure additive and 
multiplicative univariate models, except for the method of dialysis, which did not exert an effect 
on both excess and relative mortality.
Conclusion: We underlined the complementary interest of modeling excess and relative 
  mortality in looking for factors associated with mortality related to end-stage renal disease. 
The combined model appeared attractive in offering the possibility of reducing the model to 
the most appropriate one. When both components have to be retained, it better describes the 
effect of covariates on excess and relative mortality.
Keywords: additive hazard model, multiplicative hazard model, expected mortality,   generalized 
linear model, Cox model
Introduction
The increasing collection of registry-based data requires appropriate methodological 
approaches. One method of determining factors affecting chronic disease mortality 
is by analyzing cause of death. Deaths that can be directly attributed to the disease of 
interest are considered as events. Deaths from all other causes can either be censored 
to estimate the cause-specific mortality or be considered as competing events.1,2 
Unfortunately, in population-based cohorts, the cause of death is often unavailable or 
unreliable. Indeed, in patients with chronic diseases, such as end-stage renal disease 
(ESRD), the cause of death can be mistakenly imputed to their disease, whereas other 
factors, such as advanced age and associated comorbidities, play an important role Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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leading to the death. This difficulty is illustrated by a poor 
concordance between the causes of death reported on death 
certificates and in registry reports.3,4
When the cause of death cannot be used, another method 
consists of considering mortality rates from the general 
population as the natural mortality of the cohort, and thus the 
mortality due to all causes other than the cause of interest. 
Indeed, it is commonly assumed that most people from the 
general population do not present the disease of interest.5 The 
mortality rates from the general population, also called back-
ground mortality or expected mortality, are estimated from life 
tables reported in the national mortality statistics.6–8 For each 
country, these life tables give the annual probability of death 
according to sex, calendar year, and age. To take into account 
the background mortality, two measures of mortality have 
been described: the excess mortality, related to the concept of 
relative survival,5,9,10 and the relative mortality, related to the 
calculation of the standardized mortality ratio (SMR).11,12
The excess mortality is obtained by subtracting the 
expected mortality from the observed mortality (additive 
hazard model).9,10,13,14 The excess mortality can be interpreted 
as the mortality directly or indirectly related to the disease 
of interest, if one excludes all other causes of death. It is 
the extra number of deaths observed, beyond that expected, 
per   person-years. For instance, an excess mortality rate of 
40 deaths per 100 person-years means that there are 40 
additional deaths per 100 person-years in excess of those 
expected. These deaths are supposed to be related to the 
disease of interest.
The relative mortality is obtained by dividing the observed 
mortality by the expected mortality (multiplicative hazard 
model).11,13–15 The relative mortality compares the mortality 
of the cohort to the mortality of the general population. For 
instance, a relative mortality of 2 means that the observed 
mortality in the cohort is two-fold higher than expected in a 
similar subgroup of the general population.
It is worth noting that the terms “additive” and “multi-
plicative” refer to the manner in which the expected hazard 
is taken into account and not to how one considers the effect 
of covariates on excess or on relative mortality. In all this 
work, the effect of covariates on hazards is multiplicative, as 
is usually performed for common regression models (general 
linear model or Cox model).
Whereas excess and relative mortality represents differ-
ent ways of considering background mortality, the results 
of the additive model are sometimes wrongly expressed as 
relative mortality, or conversely as excess mortality for the 
multiplicative model. In addition, to our knowledge, there are 
no strong arguments in the literature for choosing an addi-
tive hazard model rather than a multiplicative hazard model. 
Excess mortality has been widely used in cancer research to 
estimate mortality in population-based studies.16–18 However, 
this method was not extensively applied to other chronic 
diseases,19,20 contrary to relative mortality.21,22
The aim of this study was to compare the information 
brought by the additive and multiplicative hazard models. 
We analyzed the independent impacts of sex, age at initiation 
of dialysis, first dialysis modality, and primary nephropathy 
on excess and relative mortality in a large population-based 
cohort of ESRD patients treated by dialysis. These models 
led to dissimilar conclusions, despite the absence of evi-
dence of lack of fit. Thus, the choice of one model instead 
of the other was not obvious. We then explored an alterna-
tive model combining both excess and relative mortality.14 
This model provides the possibility of testing the additive 
and   multiplicative components and then to reduce the model 
to the most appropriate one, either additive or multiplicative. 
The potential interest of this model is to simultaneously 
measure the effect of a covariate on both excess and rela-
tive mortality. We then present the results obtained with the 
combined model in dialyzed patients.
Materials and methods
Adult patients older than 70 years for whom dialysis was initi-
ated between 2002 and 2006 were selected from the French 
Renal Epidemiology and Information Network (REIN) 
  registry, which includes all ESRD patients on dialysis living 
in eight French regions.23,24
Duration of survival was calculated from the date of initia-
tion of dialysis until the date of death, the date of transfer for 
renal transplantation, and the date of the most recent record, 
or as of December 31, 2008, whichever came first. All analy-
ses were performed for the first 5 years of follow-up.
Individual expected hazards were calculated using sex s, 
age a, and calendar year c matched mortality rates based on 
the data of the French general population drawn from the 
Human Mortality Database (http://www.mortality.org).
All statistical analyses used R software (http://www. 
R-project.org) with the Epi package, the timereg package,25 and 
the relsurv package.26 The syntax is available in Appendix 1.
Excess mortality analysis (additive hazard 
model)
Calculation of excess mortality is based on an additive hazard 
model.9,10,13,14 The observed hazard of a cohort of patients 
suffering from the disease of interest λobs(t) is the sum of the Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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expected hazard of the general population λ*
s,a,c (t) and the 
excess hazard λexcess (t) due to the disease:
  λobs (t, z) = λ*
s,a,c (t) + λexcess (t, z)  (1)
with z the vector of covariates. Thus, the excess mortality 
is obtained by subtracting the expected mortality from the 
observed mortality:
λexcess (t, z) = λobs (t, z) - λ*
s,a,c (t)
The excess hazard is supposed to be a multiplicative 
function of the covariates z. The model (1) can be written 
as follows:
λobs (t, z) = λ*
s,a,c (t) + exp(b ′z) λ0,excess (t)
The model is a piecewise constant exponential model 
that assumes that the hazards are constant within prespeci-
fied follow-up intervals, with fu being the follow-up interval 
indicators:
λobs (t, z, fu) = λ*
s,a,c (t) + exp(b ′z + b ′fu  fu)
We chose to use a generalized linear model from indi-
vidual data.9,10 This model was estimated by splitting each 
subject i into several observations j according to the change 
in follow-up time interval (partitioned into 6-month intervals 
for the first year and into annual intervals thereafter), age of 
follow-up, and calendar year of follow-up.
We assumed that the number of deaths dj for the observa-
tion j follows a Poisson distribution with parameter µj = λj ⋅ yj 
where yj is the person-time at risk for observation j. If d*
j is 
the expected number of deaths for observation j, this model 
can be written as:
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It defines a Poisson model with the observed number of 
deaths dj as response, ln(µj - d*
j) as link function, and ln(yj) 
as offset.
Because the effect of covariates is multiplicative, dif-
ferences of excess mortality between patients with different 
covariate values (eg, Z = z0 and Z = z1) were expressed as excess 
mortality ratio (EMR) (EMR = exp(b′(z1 - z0))). For example, 
an EMR of 2 for males compared with females means that the 
excess mortality related to the disease of interest is two-fold 
higher in males than in females. An EMR of 1 means that the 
observed difference in mortality between males and females is 
similar to that observed in the general population.
A measure of the goodness of fit using the deviance 
statistic is not available with a generalized linear model 
from individual data.10,27 Goodness of fit was thus evalu-
ated from the model performed on collapsed data using the 
deviance statistics and graphical procedures as proposed by 
Stare et al.28
The relative survival (RS), from the additive hazard 
model (1), can be written as follows:5
RS tz
St z
St
obs
sac
(, )
(, )
() ,,
* =
Relative survival is a measure of the net survival, ie, the 
survival corrected for the effect of the other death causes. It 
is the probability of survival until the end of the follow-up 
period, provided that the only cause of death is the disease 
of interest.
Relative mortality analysis (multiplicative 
hazard model)
Calculation of relative mortality is based on a multiplicative 
hazard model.11,14,15 The observed hazard λobs(t) is the product 
of the expected hazard of the general population λ*
s,a,c(t) and 
the relative mortality λrel(t):
 λ obs (t, z) = λ*
s,a,c(t) ⋅ λrel (t, z)  (2)
Thus, the relative mortality is obtained by dividing the 
observed mortality by the expected mortality:
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Relative mortality provides a direct comparison between 
the observed mortality in the cohort and the mortality of the 
general population. For example, if the relative mortality of a 
given group of patients is equal to 2, it means that the mortal-
ity of this group is two-fold higher than the expected.
Of note, λrel is a hazard ratio (HR) expressed without a 
unit (whereas λexcess is a hazard, ie, a number of deaths per 
person-year).
Relative mortality can be estimated from individual data 
using a Cox model.15 The model (2) can be written as follows:
λobs (t, z) = λ*
s,a,c (t) ⋅ λ0,rel (t) ⋅ exp(b ′z)
or
λobs (t, z) = λ0,rel (t) ⋅ exp(b ′z + log(λ*
s,a,c (t)))
where λ0,rel (t) is an unknown underlying relative mortal-
ity, ie, the relative mortality at time t for an individual 
i with z = 0.Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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This model is a Cox model, including the log expected 
hazards as a time-dependent covariate with a known coef-
ficient fixed to 1 (offset). Because the effect of covariates 
is multiplicative, differences of relative mortality between 
patients with different covariate values (eg, Z = z0 and 
Z = z1) were expressed as relative mortality ratio (RMR) 
(RMR = exp(b ′(z1 - z0))). For example, an RMR of 2 for 
gender means that the ratio of the observed mortality of males 
and females is two-fold higher than the ratio of mortality of 
males and females in the general population.
Goodness  of  fit  was  evaluated  using  graphical 
procedures.29
Combining excess and relative mortality
Because it is not obvious deciding which model to choose, 
we considered a model combining both the additive and the 
multiplicative hazard components.14 This combined model 
was written as:
λobs (t) = λexcess (t) + λrel (t) ⋅ λ*
s,a,c (t)
This model is a special case of the Aalen’s additive 
linear regression model,30 where λ*
s,a,c (t) is introduced as a 
time-dependent covariate and where λexcess (t) and λrel (t) are 
the parameters to be estimated. It is possible to test whether 
λexcess (t) and λrel (t) depend on time using the Kolmogorov–
Smirnov test.25 As proposed by Andersen and Vaeth,14 because 
λexcess (t) and λrel (t) do not depend on time in our cohort of 
ESRD patients (P = 0.46 and P = 0.78, respectively), the 
model can be simplified as follows:
  λobs (t) = λexcess + λrel ⋅ λ*
s,a,c (t)  (3)
The reduction to the additive hazard model is pos-
sible by testing λrel to 1. In the same way, the reduction 
to the multiplicative hazard model is possible by testing 
λexcess to 0.
Of note, in model (3), the component λexcess is different 
from λexcess (t) in model (1). Indeed, λexcess estimated in the 
combined model does not depend on time and is estimated in 
combination with λrel. Similarly, the component λrel in model 
(3) is different from λrel (t) in model (2).
Estimation of λexcess and λrel on the whole 
cohort
The additive λexcess and multiplicative λrel components were 
estimated on the whole cohort by maximizing the log-
likelihood function (see Appendix 2). The variances of the 
parameters were estimated from the second derivative of the 
log-likelihood function (see Appendix 2).
The Wald test was used to test λexcess and λrel to 0 and 1, 
respectively.
Covariate effect on λexcess and λrel
If the λexcess is different from 0, and λrel is different from 1, model 
(3) is used to estimate the effect of the covariates on λexcess and 
λrel. The effect of the covariates on λexcess and λrel is considered 
as multiplicative, as for the additive (1) and   multiplicative (2) 
hazard models presented previously. The first step is to test the 
global effect of each covariate. We compared the models with 
and without covariate using the likelihood ratio test. Because 
it is not possible to introduce a covariate both in the additive 
and in the multiplicative component of model (3), we calcu-
lated the log-likelihoods in subgroups as follows.14 For each 
covariate we performed K submodels, one for each modality k 
of the covariate, and we tested simultaneously whether λexcess,k 
were identical and λrel,k were identical. The log-likelihood of 
the model with the covariate is the sum of the log-likelihoods 
of the K submodels. We thus compared a model with two 
parameters to a model with 2K parameters.
The second step was to test the effect of each covariate on 
the two components of the model separately. On one hand, we 
tested whether all λexcess,k were identical. On the other hand, 
we tested whether all λrel,k were identical. For example, if a 
covariate has K = 2 modalities, we tested whether λexcess,1 was 
equal to λexcess,2 by comparing the model with four parameters 
(λexcess,1, λexcess,2, λrel,1, and λrel,2) with a simplified model with 
three parameters (common λexcess, λrel,1, and λrel,2) by likelihood 
ratio test. We thus compared a model with K + 1 parameters 
to a model with 2K parameters.
Results
We identified 5206 patients who had begun dialysis between 
2002 and 2006. We excluded 91 patients for the   following 
reasons: pre-emptive graft (never dialyzed, n = 5) and 
absence of follow-up (n = 86). Finally, 5115 patients were 
included (Table 1). Mean age was 79 years (standard 
  deviation = 5.3 years, range 70–97 years). The median 
follow-up was 3 years (1 day to 5 years), and 2871 deaths 
were observed for a total of 9396 person-years.
Excess mortality analysis (additive hazard 
model)
The expected number of deaths was 518 for 2871 observed 
deaths; the excess mortality was 25 per 100 person-years. The 
1-, 2-, and 5-year relative survival rates were 77% (76%–79%), 
62% (61%–64%), and 24% (21%–28%), respectively 
(Figure 1). Univariate analysis of factors determining   Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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ddl, P = 0.23) or by graphical procedure. In particular, there 
was no interaction between age and follow-up time.
Relative mortality analysis (multiplicative 
hazard model)
The SMR on the whole cohort was 5.54 (5.34–5.75). In uni-
variate analysis, relative mortality was higher for females 
and in diabetic and tumoral/myeloma/amyloid nephropathies 
(Table 2). Older patients have a lower relative mortality. 
Multivariate analysis showed that an advanced age was 
independently associated with a lower relative mortality 
(Table 3), whereas female gender and diabetic and tumoral/
myeloma/amyloid nephropathies were independently associ-
ated with a higher relative mortality. There was no evidence 
of lack of fit by graphical procedure. In particular, there was 
no interaction between age and follow-up time.
Combining excess and relative mortality
Estimations of λexcess and λrel on the whole cohort and in sub-
groups are presented in Table 4. For the whole cohort, the 
maximum likelihood estimate of λexcess was 0.19 (±0.01) and 
was different from 0 (P , 0.001). The maximum likelihood 
estimate of λrel was 2.17 (±0.17) and was different from 1 
(P , 0.001). One might dread coping with a problem of 
identifiability in this instance. Indeed, the correlation between 
λexcess and λrel is equal to -0.82. Unfortunately, this problem 
cannot be eliminated without simulations, ie, by simulating 
data based on the combined model and assessing the ability 
of the model to estimate parameters without bias. Neverthe-
less, the previous estimations appeared coherent.
Because the two components additive and multiplicative 
should be kept, this model did not enable selection of one of 
the pure additive or multiplicative models. We thus used this 
model to estimate the effect of the covariates on both excess 
and relative mortality (Table 4).
Sex, age, and primary nephropathy exerted an effect on 
mortality; conversely, the first modality of dialysis did not. 
Moreover, we showed that λexcess was different between age 
groups and primary nephropathies, whereas λrel was higher 
in females. Both λexcess and λrel were no different between 
hemodialysis and peritoneal dialysis.
Discussion
The use of expected mortality provides a useful perspective in 
mortality analysis of population-based cohorts of patients suf-
fering from chronic disease such as cancer but also from other 
diseases. This is the reason why we were interested in comparing 
the two methods based on expected mortality rates in order to 
look for prognostic factors on ESRD-related mortality.
Table 1 Patient characteristics at the beginning of dialysis
Characteristics (whole cohort), n = 5115 Number (%)
Sex
  Male 3119 (61)
  Female 1996 (39)
Age (years)
  ,80 3125 (61)
  $80 1990 (39)
First modality of dialysis
  hemodialysis 4467 (87)
  Peritoneal dialysis 648 (13)
Primary nephropathy
  hypertensive and large vessel disease 1760 (34)
  Diabetes 1204 (23)
  Primary and secondary glomerulonephritis 360 (7)
  Interstitial nephritis/pyelonephritis 368 (7)
    Renal neoplasms/myeloma/light chain 
nephropathy/amyloidosis
241 (5)
  Miscellaneous conditions/unknown/missinga 1182 (23)
Notes:  aUnknown,  missing  (n  =  824);  miscellaneous  primary  nephropathies 
(n  =  328),  including  genetic  diseases,  mainly  represented  by  polycystic  kidney 
diseases  (n  =  143);  and  few  cases  of  developmental  anomalies  (renal  dysplasia, 
hypoplasia), cystic diseases (infantile polycystic kidneys, nephronophthisis), tubular 
necrosis (no recovery), Alport syndrome, tuberous sclerosis, cystinosis, primary 
oxalosis, and Fabry’s disease.
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Figure 1 Observed, expected, and relative survival of the whole cohort of patients 
with end-stage renal disease treated by dialysis.
excess mortality is presented in Table 2 and Figure 2. An older 
age, peritoneal dialysis, and diabetic and tumoral/myeloma/
amyloid nephropathies (compared with hypertensive/vascular 
origin) were associated with a higher excess mortality (ie, a 
poorer relative survival). Multivariate analysis showed inde-
pendent effects of age, first modality of dialysis, and diabetic 
and tumoral/myeloma/amyloid nephropathies on excess mor-
tality (Table 3). The effect of sex was not significant in the 
multivariate analysis. There was no evidence of lack of fit by 
studying deviance on collapsed data (deviance = 259 on 279 Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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Figure 2 Relative survival curves according to A) sex, B) age group, C) first dialysis modality, and D) primary nephropathy in patients with end-stage renal disease on dialysis.
Table 2 Results of the univariate analysis of factors affecting excess mortality and relative mortality in dialyzed patients
Excess mortality Relative mortality
5-year RS EMR 95% CI P value LR testa SMR RMR  95% CI P value LR testa
Sex
  Male 24% 1 3.2 4.74 1 73.6
  Female 25% 1.09 0.99–1.19 0.069 (0.1) 7.61 1.61 1.49–1.74 ,0.001 (,0.001)
Age (years)
  ,80 29% 1 65.1 7.29 1 96.1
  $80 17% 1.47 1.34–1.61 ,0.001 (,0.001) 4.34 0.59 0.55–0.64 ,0.001 (,0.001)
First modality of dialysis
  hemodialysis 26% 1 5.6 5.53 1 0.05
  Peritoneal dialysis 15% 1.17 1.03–1.34 0.014 (0.017) 5.64 1.02 0.92–1.13 0.75 (0.75)
Primary nephropathy  
  hypertensive/vascular 26% 1 98.5 4.62 1 106.4
  Diabetes 22% 1.19 1.06–1.34 0.004 (,0.001) 7.32 1.59 1.43–1.75 ,0.001 (,0.001)
  glomerulonephritis 36% 0.83 0.68–1.02 0.07 5.17 1.11 0.95–1.31 0.20
    Interstitial nephritis/ 
pyelonephritis
24% 0.91 0.75–1.11 0.36 5.32 1.15 0.98–1.34 0.09
  Tumoral/myeloma/amyloid 7% 2.46 2.06–2.93 ,0.001 14.28 3.04 2.60–3.56 ,0.001
  Miscellaneous/unknown/missing 25% 1.08 0.95–1.22 0.23 5.00 1.08 0.98–1.19 0.13
Note: aChi-squared test (P value) provided.
Abbreviations: CI, confidence interval; EMR, excess mortality ratio; LR, log-likelihood ratio; RMR, relative mortality ratio; RS relative survival, SMR, standardized 
mortality ratio.Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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The additive hazard model is almost exclusively the first-
choice model in population-based cancer studies. In other 
chronic diseases, it appears that a multiplicative hazard model is 
used more often. Noticeably, confusion between relative mortal-
ity and excess mortality is sometimes observed, ie, expressing 
the result of a multiplicative model in terms of excess mortality. 
As do Andersen and Vaeth,14 we advise using the term “excess 
mortality” when one assumes that the total hazard is the sum of 
expected and excess hazards (additive hazard model (1)). The 
term “relative mortality” should be used when one assumes 
that the total hazard is the product of expected and relative 
hazards (multiplicative hazard model (2)). We recall, in these 
two models, that the effect of covariates on excess or relative 
mortality is   considered as multiplicative.
Table 3 Results of the multivariate analysis of factors affecting excess mortality and relative mortality in dialyzed patients
Excess mortality Relative mortality
EMR 95% CI P value LR testa RMR 95% CI P value LR testa
Sex
  Male 1 1.1 1 158.2
  Female 1.05 0.96–1.15 0.29 (0.29) 1.65 1.52–1.78 ,0.001 (,0.001)
Age (years)
  ,80 1 78.5 1 162.9
  $80 1.54 1.41–1.69 ,0.001 (,0.001) 0.61 0.56–0.66 ,0.001 (,0.001)
First modality of dialysis
  hemodialysis 1 4.2 1 2.9
  Peritoneal dialysis 1.15 1.01–1.30 0.036 (0.04) 1.10 0.99–1.22 0.08 (0.1)
Primary nephropathy
  hypertensive/vascular 1 114.9 1 138.6
  Diabetes 1.29 1.14–1.45 ,0.001 (,0.001) 1.36 1.23–1.50 ,0.001 (,0.001)
  glomerulonephritis 0.92 0.75–1.13 0.42 0.99 0.84–1.16 0.88
    Interstitial nephritis/ 
pyelonephritis
0.97 0.80–1.19 0.78 1.05 0.90–1.23 0.54
  Tumoral/myeloma/amyloid 2.75 2.30–3.28 ,0.001 2.60 2.21–3.05 ,0.001
  Miscellaneous/unknown/missing 1.09 0.96–1.24 0.16 1.06 0.96–1.17 0.24
Note: aChi-squared test (P value) provided.
Abbreviations: CI, confidence interval; EMR, excess mortality ratio; LR, log-likelihood ratio; RMR, relative mortality ratio.
Table 4 Results of the combined model for modeling both excess and relative mortality in dialyzed patients
λexcess (se) Effect of the 
covariate on λexcess 
P valuea
λrel (se) Effect of the 
covariate on λrel  
P valuea
Max log 
likelihood
Effect of the covariate 
on both components  
P valuesb
Whole cohort 0.19 (0.01) 2.17 (0.17) -6169
Sex
  Male 0.17 (0.01) 2.11 (0.21) 0.0095 -3788 ,0.001
  Female 0.18 (0.01) 0.70 3.15 (0.35) -2369
Age (years)
  ,80 0.18 (0.02) 0.001 2.04 (0.44) 0.22 -2500 ,0.001
  $80 0.28 (0.03) 1.43 (0.25) -2507
First modality of dialysis
  hemodialysis 0.19 (0.01) 0.90 2.07 (0.18) 0.26 -5347 0.096
  Peritoneal dialysis 0.19 (0.03) 2.61 (0.45) -820
Primary nephropathy
  hypertensive/vascular 0.17 (0.02) 0.002 1.86 (0.26) 0.077 -2097 ,0.001
  Diabetes 0.19 (0.02) 2.99 (0.48) -1498
  glomerulonephritis 0.11 (0.03) 2.77 (0.67) -409
  Interstitial nephritis/pyelonephritis 0.10 (0.03) 3.32 (0.66) -407
  Tumoral/myeloma/amyloid 0.41 (0.08) 4.60 (1.71) -275
  Miscellaneous/unknown/missing 0.17 (0.02) 2.33 (0.31) -1420
Notes:  aLog-likelihood  ratio  test  comparing  the  k  λexcess  or  the  k  λrel;  bLog-likelihood  ratio  test  comparing  the  model  with  and  without  each  covariate  (eg,  sex: 
Chi-squared = -(3788 + 2369) + 6169).Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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Estimations of the additive hazard model are based either 
on generalized linear models10,31 or on likelihood estimation.32 
All these models produce similar estimates.10 Another type of 
additive hazard model was described by Cortese and Scheike,33 
but this model assumes an additive effect of the covariates. The 
advantage of the additive hazard model is that it is interpretable 
in the context of competing risk settings. But under some cir-
cumstances, the additive hazard model may be inappropriate 
because it requires that the risk in the diseased group be higher 
than in the general population for all covariate levels. But in 
the case of chronic diseases, there are few instances for which 
the observed mortality is lower than the expected one.
Two formulations of the multiplicative hazard model 
have been described, based on generalized linear models12 or 
the Cox proportional model,13–15 leading to close estimates. 
In this instance, the choice of a multiplicative hazard model 
has been suggested,13–15 though this was considered to be 
“biologically less appropriate” by some authors,10,13 without 
additional explanation. However, to our knowledge, there are 
no strong arguments in the literature allowing the choice of 
an additive hazard model over a multiplicative hazard model. 
A usual way of deciding which of the two models is the 
most appropriate is to examine the likelihood ratio. This is a 
nontrivial problem, as these two classes of models (Poisson 
model and Cox model) are not nested here.
This study of a large cohort of patients with ESRD treated 
by dialysis prompted us to provide a comprehensive analysis 
of the mortality and compare the two types of models. We 
chose to limit the comparison of models containing the same 
four covariates without interactions. Indeed, the complexity 
of a model including both covariate by covariate interactions 
and time by covariate interactions, especially when covariates 
have several modalities, such as in our example (primary 
nephropathies), makes the model interpretation very difficult. 
In addition, selection of the more parsimonious model should 
lead to keeping only some covariates and their interactions in 
the final additive and multiplicative models. This approach 
might possibly lead to selecting different covariates and dif-
ferent interactions for the two final models considered.
Andersen and Vaeth14 suggest considering routinely 
both age and follow-up time as underlying time variables 
when the additive and multiplicative models are evaluated. 
Indeed, it may be interesting to consider age as the under-
lying time variable in two situations: i) if healthy subjects 
are followed up prospectively for the occurrence of a given 
disease (epidemiologic cohort studies), and ii) if the data are 
left truncated. The patients were included in our cohort on 
the day they initiated dialysis. Because we were interested 
in factors affecting mortality in dialysis, we only used the 
follow-up time as a time variable.
Interestingly, most of the covariates tested in the univari-
ate models for excess or relative mortality led to different con-
clusions, particularly for age. Indeed, we observed that excess 
mortality increased with age, whereas the relative mortality 
decreased. That means that the absolute excess number of 
deaths is higher for older people (EMR = 1.54 [1.41–1.69]). 
However, relative to background mortality, which is higher in 
subjects older than 80 years, the excess of deaths was lower 
(RMR = 0.61 [0.56–0.66]). The difference between the two 
models for sex remained after adjusting for age, whereas the 
effects of first modality of dialysis and primary nephropa-
thies were similar in multivariate models. Interpreting the 
differences between the results of additive and multiplicative 
models is not straightforward. Indeed, these results must be 
examined according to i) the size of the observed mortality 
in each subgroup and the observed HR, ii) the size of the 
expected mortality in each subgroup and the expected HR, 
and iii) the size of the expected mortality relative to the 
observed mortality. There are several cases where differ-
ences between the two models occur. An interesting example 
is the effect of gender in our cohort. Indeed, we found that 
the observed mortality in males was not different from the 
observed mortality in females (observed HR = 0.99 [0.92–
1.07], P = 0.77). If gender does not exert an effect on mortal-
ity in ESRD, one should identify an observed HR for gender 
similar to the expected HR, ie, a worse prognostic in males 
(as in the general population). When performing the addi-
tive model, the EMR was not different from 1 (EMR = 1.09 
[0.99–1.19]). We explained this absence of gender effect on 
excess mortality by the fact that the expected mortality is 
very low compared with the observed mortality in our cohort. 
The ratio (λobs females - λ* females)/(λobs males - λ* males) is 
thus close to the λobs females/λobs males ratio. On the contrary, 
when performing the multiplicative model, we underlined 
that the observed HR was different from the expected HR 
(RMR = 1.61 [1.49–1.74]) and thus that gender effectively 
exerted an effect on mortality in ESRD. The results of the 
two models are thus not contradictory but complementary. 
Both models are informative, and we recommend exploring 
the results of modeling excess and relative mortality sepa-
rately in order to look for factors associated with mortality 
in chronic disease.
To our knowledge, few studies analyzed both excess and 
relative mortality using appropriate models.34–36 Kvidal et al34 
performed such analyses in men who underwent aortic 
valve replacement, Favier et al35 in Hodgkin’s lymphoma, Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
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and   Reulen et al36 in survivors of childhood cancer. In these 
studies, the opposite effect of age on relative and excess mor-
tality in univariate analysis was described. In Reulen et al,36 
the opposite effect of age disappeared in multivariate 
analysis. This opposite effect of age was not assessable 
in Kvidal et al’s34 and Favier et al’s35 studies, as they only 
performed a multivariate model for excess mortality. For 
gender, in univariate analysis, both Reulen et al36 and Favier 
et al35 described a higher relative mortality in females than 
in males, whereas the excess mortality was higher in males. 
In Reulen et al,36 the opposite effect of gender remained in 
multivariate analysis. Nevertheless, the authors did not inter-
pret this discrepancy. In the particular context of ESRD, 
excess mortality has only been used to compare differences 
in mortality on dialysis across European countries by using 
specific expected mortality rates by countries.37 In another 
study, only the relative mortality was estimated, and SMR 
was estimated and compared between various multiple 
  subgroups.38 However, our results were not comparable with 
this study, as the authors estimated SMR by subgroups and 
did not provide a multivariate analysis.
Because we observed apparent discrepancies in results 
obtained with the two models, we used the combined model 
already described by Andersen and Vaeth.14 We did not find 
in the literature a study that used such a model. This model 
has the advantage of giving the possibility of testing the 
additive and multiplicative components and then to reduce 
the model to the most appropriate one. In our data, the two 
components had to be kept in the combined model, underly-
ing the potential interest of this model in simultaneously and 
separately measuring the effect of covariates on the excess 
mortality and relative mortality. It led to results similar 
to the pure additive and multiplicative univariate models. 
  Particularly for age, the additive component became higher 
when age increased, whereas the inverse phenomenon was 
observed for the multiplicative component (even if it was 
nonsignificant). On the contrary, the modality of first dialysis 
did not exert a significant effect on both components. We 
can explain this result by the fact that the value of the addi-
tive component was very small relative to the multiplicative 
component. The omission of the multiplicative component 
(ie, if a pure additive model was used) led to an estimation 
of the additive component that might be biased, overestimat-
ing the effect of the covariate on excess   mortality. The use 
of a pure additive or multiplicative model may thus lead to 
inappropriate conclusions. In our opinion, the combined 
model appeared useful to adequately estimate the effect 
of   prognostic factors on mortality in chronic diseases. 
Nevertheless, a multivariate combined model is needed to 
confirm our results. To our knowledge, such a multivariate 
combined model has not been developed yet. Moreover, 
the interpretation of the parameters of the combined model 
is not straightforward. Presently, the parameters λexcess and 
λrel can be estimated only in subgroups. We estimated these 
parameters only for testing an effect of one covariate on 
excess and relative mortality. Because these parameters are 
not directly interpretable, further developments are neces-
sary to build a model that would estimate directly the HR for 
the two components. In this case, one might estimate both 
mortality related to a chronic disease and its relation to the 
expected mortality.
Conclusion
Excess hazard and relative hazard models allow the estima-
tion of mortality related to a chronic disease, taking into 
account the background mortality. The choice between these 
two models depends on the purpose of the analysis and the 
fit to the data. More generally, it may be interesting to look 
for factors associated with mortality in a cohort of patients 
presenting a chronic disease. Even if the interpretation of 
the excess hazard model is different from the relative hazard 
model, and if these models may lead to apparent dissimilar 
conclusions, we underlined their complementary interest in 
looking for factors associated with mortality related to ESRD. 
Alternatively, a model combining both excess and relative 
mortality gives the possibility of testing the additive and 
multiplicative components and then of reducing the model 
to the most appropriate one. When both components must be 
retained, the interest of this model is to measure simultane-
ously and separately the effect of covariates on both excess 
and relative mortality.
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Appendix 1: Syntaxes for fitting the models with R software
Fitting the additive hazard model (excess mortality analysis)
The additive hazard model is written as a generalized linear model as follows:
ln(µj - d*
j  ) = b ′z + b fu   fu + ln( yj)
The original dataset (data, one line per subject) can be easily split with the Lexis() function in the Epi package. 
For example, for one subject, data have the form:
num sex incl           age   futime D cov
70  2   04Jun2002 75.35   1.788  1   1
We need to split the follow-up of each subject into several observations j, according to change in age, calendar year, and fol-
low-up time interval (using 1-year intervals). We can thus obtain for each observation of each subject (dataset named data1):
•  Y: the length of the observation (yj)
•  rate: the expected hazard (λ*
s,a,c (t)). The website mortality.org provides a life table for each sex s (sex) containing 
the expected annual probability of death qs,a,c for each age a (age) and each calendar year c (year). The expected annual 
hazard is calculated as λ*
s,a,c = -log(1 - q*
s,a,c).
•  E: the number of expected deaths d* 
j calculated as the product of λ*
s,a,c (t) and yj
•  D: the indicator of death
•  fu: the follow-up interval indicator and
•  cov: the value of the covariate to be model.
For example, for the same subject, data1 have the form:
num sex age year rate   start  stop   Y      E      D     fu      cov
70  2   75  2002 0.0195 0.0000 0.5000 0.5000 0.0098 0 (0,0.5]     1
70  2   75  2002 0.0195 0.5000 0.5784 0.0784 0.0015 0 (0.5,1]     1
70  2   75  2003 0.0199 0.5784 0.6489 0.0705 0.0014 0 (0.5,1]     1
70  2   76  2003 0.0230 0.6489 1.0000 0.3511 0.0081 0 (0.5,1]     1
70  2   76  2003 0.0230 1.0000 1.5784 0.5784 0.0133 0 (1,2]       1
70  2   76  2004 0.0208 1.5784 1.6489 0.0705 0.0015 0 (1,2]       1
70  2   77  2004 0.0224 1.6489 1.7878 0.1389 0.0031 1 (1,2]       1
We need to specify the particular link function as   presented here:
poi <- Mypoisson()
poi$link <- “Poisson excess risk model”
poi$linkfun <- function(mu) log(mu-E)
poi$linkinv <- function(eta) exp(eta)+E
assign(“E”, data1$E, env = .GlobalEnv)
if (any(data1$D – data1$E < 0)) {
poi$initialize <- expression({
n <- rep.int(1, nobs)
mustart <- pmax(y,E) + 0.1
})
}
The model can be performed as follows with the glm() function in R software:
Add<-glm(D~-1+cov+fu,offset=log(Y),family=Mypoisson,data=data1)
The effect of the covariate is equal to the exponential of the coefficient:
EMR<-exp(coef(Add))Clinical Epidemiology 2011:3 submit your manuscript | www.dovepress.com
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Fitting the multiplicative hazard model (relative mortality analysis)
The multiplicative hazard model is written as a Cox model as follows:
λobs (t, z) = λ0,rel (t) ⋅ exp(b ′z + log(λ*
s,a,c (t)))
The original dataset (data, one line per subject) can be easily split with the Lexis() function in the Epi package. 
We need to have λ*
s,a,c (t) for each event time and thus to split the follow-up of each subject into several observations j, 
according to change in age and calendar year.
We can thus obtain for each observation of each subject (dataset named data2):
•  rate: calculated as above
•  start and stop: the limits of the observation
•  D: the indicator of death
•  cov: the value of the covariate to be model.
For example, for the same subject, data2 have the form:
num sex  age  year   rate   start stop  D cov
70  2    75   2002   0.0195 0.000 0.578 0 1
70  2    75   2003   0.0199 0.578 0.649 0 1
70  2    76   2003   0.0230 0.649 1.578 0 1
70  2    76   2004   0.0208 1.578 1.649 0 1
70  2    77   2004   0.0224 1.649 1.788 1 1
The model can be performed as follows with the coxph() function in R software:
Mult<-coxph(Surv(start,stop,D)~cov+offset(log(rate)),data=data2)
The effect of the covariate is equal to the exponential of the coefficient:
RMR<-exp(coef(Mult))
Fitting the combined model
The combined model proposed by Andersen and Vaeth14 is written as follows:
λobs (t) = λexcess (t) + λrel (t) ⋅ λ*
s,a,c (t)
We need to split the dataset as for the multiplicative hazard model (data2).
The model can be performed as follows with the aalen() function in the timereg package:
Comb<-aalen(Surv(start,stop,D)~rate,id=data2$num,data=data2)
This function allows to test whether the intercept (λexcess(t)) and the coefficient of the covariate (rate = λ*
s,a,c(t)) depend 
on time using the Kolmogorov–Smirnov test.
Appendix 2: Log-likelihood function, score vector, and Fisher information 
for the combined model
The log-likelihood function of the combined model is   written as:
( )
**
,, ,,
1 11
l n () ()
n nn
i excess rel s a c i excess i rel s a c i
i ii
LV D t t t λ λλ λ λ
= ==
= + ⋅ − ⋅ − ⋅Λ ∑ ∑∑
where ti is the observation time, Di is the indicator of failure, λ*
s,a,c(ti) is the expected hazard, and Λ*
s,a,c(ti) is the 
cumulative expected hazard for the subject i (i = 1, …, n). λexcess and λrel are the excess and the relative hazard to be   
estimated.Clinical Epidemiology
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The first-order derivative of the log-likelihood function (score vector) is written as:
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The Fisher matrix is thus equal to:
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